Drug Profile
MRG 110
Alternative Names: Anti Mir92a; MRG-110; S95010Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator University of Texas Southwestern Medical Center
- Developer Servier; University of Texas Southwestern Medical Center; Viridian Therapeutics
- Class Anti-ischaemics; Cardiovascular therapies; Heart failure therapies; Ischaemic heart disorder therapies; MicroRNAs
- Mechanism of Action MicroRNA inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Heart failure; Ischaemia; Wounds
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for phase-I development in Ischaemia(In volunteers, In adults) in USA (Intradermal, Injection)
- 28 Jun 2021 No recent reports of development identified for phase-I development in Wounds(In volunteers, In adults) in USA (Intradermal)
- 28 Apr 2021 No recent reports of development identified for phase-I development in Heart-failure in USA